{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000118","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.729639+00:00","generated_at":"2026-06-12T01:17:37.481172+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiora Q2 net loss $2.6M; ABACUS phase 1b shows KIO-301 proof-of-concept in retinitis pigmentosa","bullets":["Net loss $2.6M in Q2 2023 vs $2.4M Q2 2022; cash $8.0M at quarter end.","Preliminary ABACUS data: KIO-301 safe/tolerable with positive vision impact; topline results expected Q4 2023.","Sharpened focus on rare retinal diseases; KIO-301 trials to expand to choroideremia and Stargardt's disease.","Shifted resources from KIO-101 (ocular RA) to KIO-104 (posterior uveitis); seeking partnerships for anterior segment programs.","Raised $6.3M funding extending runway to May 2024; received $1.2M in R&D tax credits from Australia and Austria."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000118","json":"https://secwatch.observer/filing/0001372514-23-000118.json","markdown":"https://secwatch.observer/filing/0001372514-23-000118.md","text":"https://secwatch.observer/filing/0001372514-23-000118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/0001372514-23-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/kprx-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:17:37.481172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99694c666625d2cfd7be42775c2f73fc8260692d","claim":"KIORA PHARMACEUTICALS INC reported second quarter 2023 results: net income Net loss was $2.6 million for the second quarter of 2023.","evidence_excerpt":"On August 8, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended June 30, 2023 and an update on clinical development progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/0001372514-23-000118-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"Net loss was $2.6 million for the second quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}